The best-validated targeted drugs in melanoma are the selective BRAF inhibitors vemurafenib (PLX4032, ZelborafTM) and dabrafenib (GSK2118436, TafinlarTM) as well as the LGX818 (Novartis) compound that appears to have the highest affinity for the catalytic domain of the kinase. This evidence concerns the gene BRAF and melanoma.